Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
1.
Tran, K. B.; Lang, J. J.; Compton, K.; Xu, R. X.; Acheson, A. R.; Henrikson, H. J.; Kocarnik, J. M.; Penberthy, L.; Aali, A.; Abbas, Q.; Abbasi, B.; Abbasi-Kangevari, M.; Abbasi-Kangevari, Z.; Abbastabar, H.; Abdelmasseh, M.; Abd-Elsalam, S.; Abdelwahab, A. A.; Abdoli, G.; Abdulkadir, H. A.; Abedi, A.; Abegaz, K. H.; Abidi, H.; Aboagye, R. G.; Abolhassani, H.; Absalan, A.; Abtew, Y. D.; Ali, H. A.; Abu-Gharbieh, E.; Achappa, B.; Acuna, J. M.; Addison, D.; Addo, I. Y.; Adegboye, O. A.; Adesina, M. A.; Adnan, M.; Adnani, Q. E. S.; Advani, S. M.; Afrin, S.; Afzal, M. S.; Aggarwal, M.; Ahinkorah, B. O.; Ahmad, A. R.; Ahmad, R.; Ahmad, S.; Ahmadi, S.; Ahmed, H.; Ahmed, L. A.; Ahmed, M. B.; Rashid, T. A.; Aiman, W.; Ajami, M.; Akalu, G. T.; Akbarzadeh-Khiavi, M.; Aklilu, A.; Akonde, M.; Akunna, C. J.; Al Hamad, H.; Alahdab, F.; Alanezi, F. M.; Alanzi, T. M.; Alessy, S. A.; Algammal, A. M.; Al-Hanawi, M. K.; Alhassan, R. K.; Ali, B. A.; Ali, L.; Ali, S. S.; Alimohamadi, Y.; Alipour, V.; Aljunid, S. M.; Alkhayyat, M.; Al-Maweri, S. A. A.; Almustanyir, S.; Alonso, N.; Alqalyoobi, S.; Al-Raddadi, R. M.; Al-Rifai, R. H. H.; Al-Sabah, S. K.; Al-Tammemi, A. B.; Altawalah, H.; Alvis-Guzman, N.; Amare, F.; Ameyaw, E. K.; Dehkordi, J. J. A.; Amirzade-Iranaq, M. H.; Amu, H.; Amusa, G. A.; Ancuceanu, R.; Anderson, J. A.; Animut, Y. A.; Anoushiravani, A.; Anoushirvani, A. A.; Ansari-Moghaddam, A.; Ansha, M. G.; Antony, B.; Antwi, M. H.; Anwar, S. L.; Anwer, R.; Anyasodor, A. E.; Arabloo, J.; Arab-Zozani, M.; Aremu, O.; Argaw, A. M.; Ariffin, H.; Aripov, T.; Arshad, M.; Al, Artaman, Arulappan, J.; Aruleba, R. T.; Aryannejad, A.; Asaad, M.; Asemahagn, M. A.; Asemi, Z.; Asghari-Jafarabadi, M.; Ashraf, T.; Assadi, R.; Athar, M.; Athari, S. S.; Null, Mmwa, Attia, S.; Aujayeb, A.; Ausloos, M.; Avila-Burgos, L.; Awedew, A. F.; Awoke, M. A.; Awoke, T.; Quintanilla, B. P. A.; Ayana, T. M.; Ayen, S. S.; Azadi, D.; Null, S. A.; Azami-Aghdash, S.; Azanaw, M. M.; Azangou-Khyavy, M.; Jafari, A. A.; Azizi, H.; Azzam, A. Y. Y.; Babajani, A.; Badar, M.; Badiye, A. D.; Baghcheghi, N.; Bagheri, N.; Bagherieh, S.; Bahadory, S.; Baig, A. A.; Baker, J. L.; Bakhtiari, A.; Bakshi, R. K.; Banach, M.; Banerjee, I.; Bardhan, M.; Barone-Adesi, F.; Barra, F.; Barrow, A.; Bashir, N. Z.; Bashiri, A.; Basu, S.; Batiha, A. M. M.; Begum, A.; Bekele, A. B.; Belay, A. S.; Belete, M. A.; Belgaumi, U. I.; Bell, A. W.; Belo, L.; Benzian, H.; Berhie, A. Y.; Bermudez, A. N. C.; Bernabe, E.; Bhagavathula, A. S.; Bhala, N.; Bhandari, B. B.; Bhardwaj, N.; Bhardwaj, P.; Bhattacharyya, K.; Bhojaraja, V. S.; Bhuyan, S. S.; Bibi, S.; Bilchut, A. H.; Bintoro, B. S.; Biondi, A.; Birega, M. G. B.; Birhan, H. E.; Bjorge, T.; Blyuss, O.; Bodicha, B. B. A.; Bolla, S. R.; Boloor, A.; Bosetti, C.; Braithwaite, D.; Brauer, M.; Brenner, H.; Briko, A. N.; Briko, N. I.; Buchanan, C. M.; Bulamu, N. B.; Bustamante-Teixeira, M. T.; Butt, M. H.; Butt, N. S.; Butt, Z. A.; dos Santos, F. L. C.; Camera, L. A.; Cao, C.; Cao, Y.; Carreras, G.; Carvalho, M.; Cembranel, F.; Cerin, E.; Chakraborty, P. A.; Charalampous, P.; Chattu, V. K.; Chimed-Ochir, O.; Chirinos-Caceres, J. L.; Cho, D. Y.; Cho, W. C. S.; Christopher, D. J.; Chu, D. T.; Chukwu, I. S.; Cohen, A. J.; Conde, J.; Cortas, S.; Costa, V. M.; Cruz-Martins, N.; Culbreth, G. T.; Dadras, O.; Dagnaw, F. T.; Dahlawi, S. M. A.; Dai, X. C.; Dandona, L.; Dandona, R.; Daneshpajouhnejad, P.; Danielewicz, A.; Dao, A. T. M.; Soltani, R. D. C.; Darwesh, A. M.; Das, S.; Davitoiu, D. V.; Esmaeili, E. D.; De la Hoz, F. P.; Debela, S. A.; Dehghan, A.; Demisse, B.; Demisse, F. W.; Denova-Gutierrez, E.; Derakhshani, A.; Molla, M. D.; Dereje, D.; Deribe, K. S.; Desai, R.; Desalegn, M. D.; Dessalegn, F. N.; Dessalegni, S. A. A.; Dessie, G.; Desta, A. A.; Dewan, S. M. R.; Dharmaratne, S. D.; Dhimal, M.; Dianatinasab, M.; Diao, N.; Diaz, D.; Digesa, L. E.; Dixit, S. G.; Doaei, S.; Doan, L. P.; Doku, P. N.; Dongarwar, D.; dos Santos, W. M.; Driscoll, T. R.; Dsouza, H. L.; Durojaiye, O. C.; Edalati, S.; Eghbalian, F.; Ehsani-Chimeh, E.; Eini, E.; Ekholuenetale, M.; Ekundayo, T. C.; Ekwueme, D. U.; El Tantawi, M.; Elbahnasawy, M. A.; Elbarazi, I.; Elghazaly, H.; Elhadi, M.; El-Huneidi, W.; Emamian, M. H.; Bain, L. E.; Enyew, D. B.; Erkhembayar, R.; Eshetu, T.; Eshrati, B.; Eskandarieh, S.; Espinosa-Montero, J.; Etaee, F.; Etemadimanesh, A.; Eyayu, T.; Ezeonwumelu, I. J.; Ezzikouri, S.; Fagbamigbe, A. F.; Fahimi, S.; Fakhradiyev, I. R.; Faraon, E. J. A.; Fares, J.; Farmany, A.; Farooque, U.; Farrokhpour, H.; Fasanmi, A. O.; Fatehizadeh, A.; Fatima, W.; Fattahi, H.; Fekadu, G.; Feleke, B. E.; Ferrari, A. A.; Ferrero, S.; Desideri, L. F.; Filip, I.; Fischer, F.; Foroumadi, R.; Foroutan, M.; Fukumoto, T.; Gaal, P. A.; Gad, M. M.; Gadanya, M. A.; Gaipov, A.; Galehdar, N.; Gallus, S.; Garg, T.; Fonseca, M. G.; Gebremariam, Y. H.; Gebremeskel, T. G.; Gebremichael, M. A.; Geda, Y. F.; Gela, Y. Y.; Gemeda, B. N. B.; Getachew, M.; Getachew, M. E.; Ghaffari, K.; Ghafourifard, M.; Ghamari, S. H.; Nour, M. G.; Ghassemi, F.; Ghimire, A.; Ghith, N.; Gholamalizadeh, M.; Navashenaq, J. G.; Ghozy, S.; Gilani, S. A.; Gill, P. S.; Ginindza, T. G.; Gizaw, A. T. T.; Glasbey, J. C.; Godos, J.; Goel, A.; Golechha, M.; Goleij, P.; Golinelli, D.; Golitaleb, M.; Gorini, G.; Goulart, B. N. G.; Grosso, G.; Guadie, H. A.; Gubari, M. I. M.; Gudayu, T. W.; Guerra, M. R.; Gunawardane, D. A.; Gupta, B.; Gupta, S.; Gupta, V.; Gupta, V. K.; Gurara, M. K.; Guta, A.; Habibzadeh, P.; Avval, A. H.; Hafezi-Nejad, N.; Ali, A. H.; Haj-Mirzaian, A.; Halboub, E. S.; Halimi, A.; Halwani, R.; Hamadeh, R. R.; Hameed, S.; Hamidi, S.; Hanif, A.; Hariri, S.; Harlianto, N. I.; Haro, J. M.; Hartono, R. K.; Hasaballah, A. I.; Hasan, S. M. M.; Hasani, H.; Hashemi, S. M.; Hassan, A. M.; Hassanipour, S.; Hayat, K.; Heidari, G.; Heidari, M.; Heidarymeybodi, Z.; Herrera-Serna, B. Y.; Herteliu, C.; Hezam, K.; Hiraike, Y.; Hlongwa, M. M.; Holla, R.; Holm, M.; Horita, N.; Hoseini, M.; Hossain, M. M.; Hossain, M. B. H.; Hosseini, M. S.; Hosseinzadeh, A.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Househ, M.; Huang, J. J.; Hugo, F. N.; Humayun, A.; Hussain, S.; Hussein, N. R.; Hwang, B. F.; Ibitoye, S. E.; Iftikhar, P. M.; Ikuta, K. S.; Ilesanmi, O. S.; Ilic, I. M.; Ilic, M. D.; Immurana, M.; Innos, K.; Iranpour, P.; Irham, L. M.; Islam, M. S.; Islam, R. M.; Islami, F.; Ismail, N. E.; Isola, G.; Iwagami, M.; Merin, J. L.; Jaiswal, A.; Jakovljevic, M.; Jalili, M.; Jalilian, S.; Jamshidi, E.; Jang, S. I.; Jani, C. T.; Javaheri, T.; Jayarajah, U. U.; Jayaram, S.; Jazayeri, S. B.; Jebai, R.; Jemal, B.; Jeong, W.; Jha, R. P.; Jindal, H. A.; John-Akinola, Y. O.; Jonas, J. B.; Joo, T.; Joseph, N.; Joukar, F.; Jozwiak, J. J.; Jarisson, M.; Kabir, A.; Kacimi, S. E. O.; Kadashetti, V.; Kahe, F.; Kakodkar, P. V.; Kalankesh, L. R.; Kalhor, R.; Kamal, V. K.; Kamangar, F.; Kamath, A.; Kanchan, T.; Kandaswamy, E.; Kandel, H.; Kang, H.; Kanno, G. G.; Kapoor, N.; Kar, S. S.; Karanth, S. D.; Karaye, I. M.; Karch, A.; Karimi, A.; Kassa, B. G.; Katoto, Pdmc, Kauppila, J. H.; Kaur, H.; Kebede, A. G.; Keikavoosi-Arani, L.; Kejela, G. G.; Bohan, P. M. K.; Keramati, M.; Keykhaei, M.; Khajuria, H.; Khan, A.; Khan, A. A. K.; Khan, E. A.; Khan, G.; Khan, M. N.; Ab Khan, M.; Khanali, J.; Khatab, K.; Khatatbeh, M. M.; Khatib, M. N.; Khayamzadeh, M.; Kashani, H. R. K.; Tabari, M. A. K.; et al..
Lancet ; 400(10352):563-591, 2022.
Article in English | Web of Science | ID: covidwho-2068419

ABSTRACT

Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

2.
Clinical Lymphoma, Myeloma and Leukemia ; 22(Supplement 2):S411, 2022.
Article in English | EMBASE | ID: covidwho-2062040

ABSTRACT

Context: CARTITUDE-2 (NCT04133636) Cohort A is assessing cilta-cel in lenalidomide-refractory patients with progressive MM after 1-3 prior LOT. Objective(s): To present updated results from CARTITUDE-2 Cohort A. Design(s): Phase 2, multicohort study. Patient(s): Lenalidomide-refractory patients with progressive MM after 1-3 prior LOT (PI and IMiD included) and no previous exposure to BCMA-targeting agents. Intervention(s): Single cilta-cel infusion (target dose 0.75x106 CAR+ viable T-cells/kg) after lymphodepletion Main Outcome Measure(s): Primary endpoint was minimal residual disease (MRD) negativity at 10-5. Management strategies were used to reduce risk of movement/neurocognitive adverse events (MNTs). Pharmacokinetics (PK) (Cmax/Tmax of CAR+T-cell transgene levels), cytokine release syndrome (CRS)-related cytokines over time, peak cytokine levels by response/CRS, association of cytokine levels with immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR+T-cell CD4/CD8 ratio by response/CRS/ICANS are being evaluated. Result(s): As of January 2022 (median follow-up [MFU] 17.1 months), 20 patients (65% male;median age 60 years;median 2 prior LOT;95% refractory to last LOT) received cilta-cel. Overall response rate was 95% (90% >=complete response;95% >=very good partial response). Median times to first and best response were 1.0 month and 2.6 months, respectively. All 16 MRD-evaluable patients achieved MRD negativity at 10-5. Median duration of response was not reached. At 12 months, event-free rate was 79% and progression-free survival rate was 75%. 95% of patients had CRS (gr3/4 10%);median time to onset was 7 days and median duration was 3 days. Neurotoxicity was reported in 30% of patients (5 gr1/2;1 gr3/4) and ICANS in 15% (all 3 gr1/2);1 patient had gr2 facial paralysis. No MNTs were observed. 1 death occurred due to COVID-19 (treatment-related), 2 due to progressive disease, and 1 due to sepsis (not treatment-related). Preliminary PK analyses showed peak CAR-T cell expansion at day 10.5;median persistence was 153.5 days. Conclusion(s): At MFU of 17.1 months, a single cilta-cel infusion resulted in deep and durable responses in lenalidomide-refractory MM patients with 1-3 prior LOT. We will present updated PK/cytokine/CAR-T subset analyses and clinical correlation to provide novel insights into biological correlates of efficacy/safety in this population. Copyright © 2022 Elsevier Inc.

3.
17th European Conference on Technology Enhanced Learning, EC-TEL 2022 ; 13450 LNCS:59-73, 2022.
Article in English | Scopus | ID: covidwho-2048153

ABSTRACT

The COVID-19 crisis emphasizes the importance of Self-Regulated Learning (SRL), one of today’s most valuable skills, with which learners set their learning goals, monitor and control their cognition, motivation, and behavior, and reflect upon them. In the current experimental study, an intervention program based on short online interactive videos was developed to promote SRL skills. This paper presents the impact of the intervention on students’ use of SRL skills and grades. It also explores four key pedagogical processes (teacher-student relationships, collaboration, autonomy, and feedback) as mediators for SRL strategies use and grades. The experimental and control groups were randomly assigned (N = 290 students, 18 classes, grades 7–12). Each teacher taught the same subject in two classes for a month, an amount of time that allows intervention to take effect. One of the classes participated in the video-based intervention program (experimental group), whereas the other performed all activities but did not have access to the videos (control group). Data was collected through an SRL and pedagogies usage questionnaire, SRL video prompts, and knowledge tests and was analyzed using the quantitative method. In addition to the theoretical contribution, a practical tool has been developed for educators who wish to employ online SRL training. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.

4.
J Am Acad Dermatol ; 87(3):AB43, 2022.
Article in English | PMC | ID: covidwho-2041852
5.
Annals of Emergency Medicine ; 78(4 Suppl):S123-S124, 2021.
Article in English | GIM | ID: covidwho-2035735

ABSTRACT

Background: Fluid boluses are amongst the strongest recommendations for the management of septic patients, and they are generally administered with the goal increasing cardiac output and improving tissue perfusion. Early identification of volume responsiveness is challenging and dependent on many patient factors, but it may prevent the harmful consequences of hypervolemia. Left ventricular outflow tract (LVOT) velocity time integral (VTI) has been used as a predictor of volume responsiveness. Study Objectives: The purpose of this study was to determine whether lack of volume responsiveness, defined as =15% change in LVOT VTI, is associated with increased risk of mortality, admission to an intensive care unit (ICU), or rapid response team activation within 24 hours of hospital arrival (composite outcome measure). We hypothesize that septic patients who are not volume responders will be more critically ill and therefore at greater risk of experiencing the composite outcome.

6.
Aims Public Health ; 9(4):630-643, 2022.
Article in English | Web of Science | ID: covidwho-2033208

ABSTRACT

We sought to explore mental health and psychosocial impact among young people (18 to 24 years old) in Bogota during the first months of the COVID-19 pandemic. Methods: We carried a cross sectional study using a web-based survey to assess mental health and personal impact among 18 to 24 years old living in Bogota during the first 4 months of the 2020 COVID-19 pandemic lockdown. The depressive symptoms were measured with PHQ-8 and anxiety symptoms with (GAD-7). We also designed a questionnaire exploring changes in personal, family and social life. Results: Overall, 23% of the sample (n = 834) reported mild depressive symptoms (males 24% and females 23%);29% reported moderate depressive symptoms (males 28%, females 30%);22% moderate-severe symptoms (males 20%, females 23%) and 17% severe symptoms (males 15%, females 17%). Mild anxiety symptoms were reported by 29% of the sample (males 30%, females 29%);moderate anxiety symptoms by 29% (males 26%, females 30%);moderate-severe 18% (males 15%, females 20%) and severe anxiety by 6.0% (males 6.0% and females 6.0%). High symptoms of depression (PHQ-8 >= 10) were associated with being female, considering that the quarantine was stressful, having one member of the family losing their job, worsening of family relationships, decrease of physical activity and having a less nutritious diet. Having high anxiety symptoms (GAD-7 >= 10) were associated with sometimes not having enough money to buy food. Conclusions: The first months of the pandemic lockdown were associated with high depressive and anxiety symptoms among young persons living in Bogota, Colombia. Increasing public health measures to provide support for young people is needed during lockdowns and it is necessary to further explore the long-term mental health impact due to personal, family and social changes brought by the COVID-19 pandemic.

7.
HemaSphere ; 6:1630-1631, 2022.
Article in English | EMBASE | ID: covidwho-2032118

ABSTRACT

Background: Cohort A of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study is assessing ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in patients with multiple myeloma (MM) who received 1-3 prior lines of therapy (LOT) and were refractory to lenalidomide (len). This population is difficult to treat and has poor prognosis. Aims: To present updated results from CARTITUDE-2 Cohort A. Methods: All patients provided informed consent. Eligible patients had progressive MM after 1-3 prior LOT that included a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD). Patients were len-refractory and had no prior exposure to BCMA-targeting agents. Patients received a single cilta-cel infusion (target dose: 0.75×106 CAR+ viable T cells/kg) after lymphodepletion. Cilta-cel safety and efficacy were assessed. The primary endpoint was minimal residual disease (MRD) negativity at 10-5 by next generation sequencing. Patient management strategies were used to reduce the risk of movement and neurocognitive adverse events (MNTs). Other assessments included pharmacokinetic (PK) analyses (Cmax and Tmax of CAR+ T-cell transgene levels in blood), levels of cytokine release syndrome (CRS)-related cytokines (e.g., IL-6) over time, peak levels of cytokines by response and CRS, association of cytokine levels with immune effector cell-associated neurotoxicity syndrome (ICANS), and CAR+ T cell CD4/CD8 ratio by response, CRS, and ICANS. Results: As of January 2022 (median follow-up: 17.1 months [range: 3.3-23.1]), cilta-cel was administered to 20 patients (male: 65%;median age: 60 years [range: 38-75]). Median number of prior LOT was 2 (range: 1-3);median time since MM diagnosis was 3.5 years (range: 0.7-8.0). 95% of patients were refractory to their last LOT;40% were triple-class refractory. Overall response rate was 95%, with 90% of patients achieving ≥complete response and 95% achieving ≥very good partial response. Median time to first response was 1.0 month (range: 0.7-3.3);median time to best response was 2.6 months (range: 0.9-13.6). All MRD-evaluable patients (n=16) achieved MRD negativity at 10-5. Median duration of response was not reached. The 12-month progression-free survival rate was 75% and the 12-month event-free rate was 79%. CRS occurred in 95% of patients (grade 3/4: 10%), with a median time to onset of 7 days (range: 5-9) and median duration of 3 days (range: 2-12). 30% of patients had neurotoxicity (5 grade 1/2 and 1 grade 3/4). ICANS occurred in 3 patients (15%;all grade 1/2);1 patient had facial paralysis (grade 2). No MNTs were observed. 1 death due to COVID-19 occurred and was assessed as treatment-related by the investigator;2 deaths due to progressive disease and 1 due to sepsis (not related to treatment) also occurred. Based on preliminary PK analyses of CAR transgene by qPCR, peak expansion of CAR-T cells occurred at day 10.5 (range: 8.7-42.9);median persistence was 153.5 days (range: 57.1-336.8). Summary/Conclusion: A single cilta-cel infusion led to deepening and durable responses at this longer follow-up (median 17.1 months) in patients with MM who had 1-3 prior LOT and were len-refractory. Follow-up is ongoing. We will present updated and detailed PK, cytokine, and CAR-T subset analyses as well as clinical correlation to provide novel insights into biological correlates of efficacy and safety in this difficult-to-treat patient population, which is being further evaluated in the CARTITUDE-4 study (NCT04181827;enrollment concluded).

8.
Journal of the American Academy of Dermatology ; 87(3):AB115, 2022.
Article in English | EMBASE | ID: covidwho-2031384

ABSTRACT

Background: The COVID-19 pandemic sparked increased utilization of telemedicine services, as telemedicine offers care at a safe distance. Dermatology is well-suited for telemedicine due to its visual nature;however, concerns regarding diagnostic accuracy limit its widespread use. Visits for certain types of concerns may be more conducive to virtual visits than others. Further study of teledermatology may reveal trends in visit types and influence future integration into practice. Methods: Thomas Jefferson University analyzed aggregated, de-identified data from FAIR Health’s FH NPIC repository of privately insured medical claims, for telehealth services performed by dermatologists between 2019 and 2020 at urban and rural levels. Calculations were performed to determine the percentage of teledermatology visits that used specific diagnosis codes relative to all teledermatology visits. Visits were also assessed for the following parameters: demographics, diagnosis codes, and procedure codes. Results: Diagnosis codes L70.0 and L71.0, which primarily pertain to acne and rosacea, comprised 61% and 75% of Disorders of Skin Appendages teledermatology claims in 2019 and 2020 respectively. In 2019, teledermatology visits most often used diagnosis codes L60-75 in both urban and rural locations (33.7% and 31.9%, respectively). Moreover, from 2019 to 2020, the percentage of teledermatology visits that used codes L60-75 was 1.35 times greater in urban locations and 1.48 times greater in rural locations. Conclusions: Teledermatology visits favored specific diagnoses, specifically pertaining to acne and rosacea. This suggests that these diagnoses may be more conducive to virtual visits relative to other diagnoses such as skin neoplasms or papulosquamous disorders, including psoriasis.

9.
Journal of Clinical Oncology ; 40(16), 2022.
Article in English | EMBASE | ID: covidwho-2005666

ABSTRACT

Background: Cohort A of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study is evaluating cilta-cel safety and efficacy in pts with MM who received 1-3 prior LOT and were len-refractory - a difficult- to-treat population with poor prognosis. We present updated results. Methods: Pts had progressive MM after 1-3 prior LOT, including a PI and IMiD, were len-refractory, and had no prior exposure to BCMA-targeting agents. A single cilta-cel infusion (target dose 0.75×106 CAR+ viable T cells/kg) was given post lymphodepletion. Safety and efficacy were assessed, and the primary endpoint was MRD negativity at 10-5. Management strategies were implemented to minimize risk of movement/neurocognitive AEs (MNTs). Pharmacokinetic (PK) analyses (Cmax and Tmax of CAR+ T-cell transgene levels in blood) are being conducted, as well as analyses of levels of CRS-related cytokines (eg, IL-6) over time, peak levels of cytokines by response and CRS, association of cytokine levels with ICANS, and CAR+ T cell CD4/CD8 ratio by response, CRS, and ICANS. Results: As of January 2022 (median follow- up [MFU] 17.1 mo [range 3.3-23.1]), 20 pts (65% male;median age 60 y [range 38-75]) received cilta-cel. Pts received a median of 2 (range 1-3) prior LOT, and a median of 3.5 y (range 0.7-8.0) since MM diagnosis. 95% were refractory to last LOT, and 40% were triple-class refractory. ORR was 95%, 90% achieved CR or better, and 95% had ≥VGPR. Median times to first and best response were 1.0 mo (range 0.7-3.3) and 2.6 mo (range 0.9-13.6), respectively. 16 pts were MRDevaluable, all of whom achieved MRD negativity at 10-5. Median DOR was not reached and 12-mo event-free rate was 79%. The 12-mo PFS rate was 75%. Median time to onset of CRS was 7 d (range 5-9) and occurred in 95% of pts (gr 3/4: 10%), with median duration of 3 d (range 2-12). Neurotoxicity occurred in 30% of pts (5 gr 1/2;1 gr 3/4). 3 pts (15%) had ICANS (all gr 1/2);1 pt had gr 2 facial paralysis. No MNTs were seen. 1 death occurred due to COVID-19 (assessed as tx-related by the investigator), 2 due to progressive disease, and 1 due to sepsis (not related to tx). Preliminary PK analyses indicate that peak expansion of CAR-T cells occurred at d 10.5 (range 8.7-42.9) and median persistence was 153.5 d (range 57.1-336.8). Conclusions: At a longer MFU of 17.1 mo, a single cilta-cel infusion led to deepening and durable responses in pts with MM who had 1-3 prior LOT and were lenrefractory. Follow-up is ongoing. Updated and in-depth PK, cytokine, and CAR-T subset analyses and clinical correlation will be presented and provide novel insights into biological correlates of efficacy and safety in this pt population. This pt population is being further evaluated in the CARTITUDE-4 study (NCT04181827), which has concluded enrollment.

10.
33rd ACM Conference on Hypertext and Social Media, HT 2022 - Co-located with ACM WebSci 2022 and ACM UMAP 2022 ; : 121-131, 2022.
Article in English | Scopus | ID: covidwho-1962411

ABSTRACT

Classifying moral values in user-generated text from social media is critical in understanding community cultures and interpreting user behaviors of social movements. Moral values and language usage can change across the social movements;however, text classifiers are usually trained in source domains of existing social movements and tested in target domains of new social issues without considering the variations. In this study, we examine domain shifts of moral values and language usage, quantify the effects of domain shifts on the morality classification task, and propose a neural adaptation framework via instance weighting to improve cross-domain classification tasks. The quantification analysis suggests a strong correlation between morality shifts, language usage, and classification performance. We evaluate the neural adaptation framework on a public Twitter data across 7 social movements and gain classification improvements up to 12.1%. Finally, we release a new data of the COVID-19 vaccine labeled with moral values and evaluate our approach on the new target domain. For the case study of the COVID-19 vaccine, our adaptation framework achieves up to 5.26% improvements over neural baselines. This is the first study to quantify impacts of moral shifts, propose adaptive framework to model the shifts, and conduct a case study to model COVID-19 vaccine-related behaviors from moral values. © 2022 ACM.

11.
American Journal of Respiratory and Critical Care Medicine ; 205(1), 2022.
Article in English | EMBASE | ID: covidwho-1927803

ABSTRACT

Rationale: Although mortality from COVID-19 increases with advanced age, most older adults survive a COVID hospitalization. Disability, or dependence in functional activities, is known to increase after a serious illness among older adults, with adverse consequences for patients, families, and society. Little is known about disability, and the factors associated with disability, after a COVID hospitalization among older adults. Methods: We enrolled 341 older (≥60 years) adults during their index COVID-19 hospitalization between 7/6/2020-6/24/2021 from five hospitals in the Yale-New Haven Health System. Upon enrollment, participants underwent an assessment of baseline (prehospitalization) disability, frailty, general health, social support, hearing, vision, mental health, and assessments of current (in-hospital) symptom burden and cognitive function. These assessments were linked to EMR data including demographics, SOFA score, comorbidities, biomarkers, respiratory support, pressors, length of stay, and COVIDspecific treatments. Disability was assessed at baseline and 1, 3, and 6 months by asking about dependence in 15 basic, instrumental, and mobility activities. The primary outcome was the disability count (0-15) over the 6 months after the COVID hospitalization. The analytic sample included 304 participants who survived their hospitalization and had at least one post-discharge follow-up. We determined the mean (SD) number of disabilities over the 6 months after discharge and evaluated 27 factors for their association with the 6-month disability count using backwards selection based on minimization of the Bayesian Information Criterion with a zero-inflated negative binomial distribution and adjustment for baseline disability count and months of follow-up. Results: The mean age was 71.2 years (SD 8.5), 158 (51.8%) were women, and 108 (35.5%) were of nonwhite race or Hispanic ethnicity (Table). The mean prehospitalization disability count was 2.2 (SD 3.4), and the mean disability count over the 6 months after the COVID hospitalization was 2.9 (SD 3.7). In the multivariable model, greater baseline disability, older age, higher BMI, higher comorbidity count, cognitive dysfunction, greater symptom burden during the hospitalization, and the need for advanced respiratory support were all associated with greater disability over the 6 months after a COVID hospitalization. Conclusions: Other than the need for advanced respiratory support, factors associated with disability after a COVID hospitalization among older adults reflect vulnerability at baseline (comorbidities, baseline disability, age, BMI) or during the hospitalization (symptom burden, cognitive dysfunction), rather than biomarkers or severity of illness. These factors may identify older adults for referral to Post-COVID clinic programs to improve the likelihood of functional recovery after discharge. (Table Presented).

12.
Journal of Agriculture Food Systems and Community Development ; 11(3):18, 2022.
Article in English | Web of Science | ID: covidwho-1918019

ABSTRACT

In this paper, we report on research findings from a cross-sectional survey with 143 primarily Mexican migrant agricultural worker respondents in British Columbia (BC), Canada. Participants reported high rates of experiences of threats and violence by employers, limited faith in the follow-through of both Canadian and country-of-origin authorities when reporting concerns, and a unanimous lack of knowledge in how to file a claim of a legal matter (e.g., housing, human rights violation). Most participants also reported that they believed they would receive poorer health care in relation to their Canadian counterparts and that their privacy would not be protected. While certain indicators, such as knowledge of resources for transportation, translation, and legal advocacy were higher than previous research would suggest, most participants did not feel confident that more serious issues would be addressed if they sought help. Our results suggest migrant workers in BC report similar, or even higher, rates of experiences and expectations of poor social support, legal protection, and health care in comparison to prior research in this region and elsewhere. While further research would be required to confirm this hypothesis, the impact of COVID-19 on this population is undeniable. Our findings highlight the need for greater regional and provincial commitments to fund targeted services for migrant agricultural workers that address the unique barriers they face. Additionally, greater attention and funding must be dedicated to supporting this population to navigate and access services that already exist. Together, dedicated initiatives could make a major difference for this workforce. Federal investments in support services of this nature would ensure the sustainability of such efforts. In addition, reforms to temporary migrant agricultural programs, such as open work permits and immediate access to permanent residence, would better afford workers opportunities to access the rights and protections that are currently out of reach for many.

13.
HemaSphere ; 6(SUPPL 2):15, 2022.
Article in English | EMBASE | ID: covidwho-1915866

ABSTRACT

Introduction: Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell (CAR-T) therapy expressing two B-cell maturation antigen (BCMA)-targeting, single-domain antibodies. The multicohort, open-label, phase 2 CARTITUDE-2 study (NCT04133636) is assessing cilta-cel in patients (pts) with multiple myeloma (MM) under various clinical settings and evaluating the suitability of outpatient administration. Updated results of CARTITUDE-2 cohort A are presented here. Methods: Cohort A pts had progressive MM after 1-3 prior lines of therapy (LOT;included proteasome inhibitor [PI] and immunomodulatory drug [IMiD]), were lenalidomide-refractory, and had no previous exposure to BCMA-targeting agents. A single cilta-cel infusion at a target dose of 0.75×106 CAR+ viable T cells/kg was given 5-7 d after start of lymphodepletion (cyclophosphamide [300 mg/m2] and fludarabine [30 mg/m2] for 3 d). The primary endpoint was minimal residual disease (MRD) negativity at 10-5 at any time point. Secondary endpoints were overall response rate (ORR), duration of response (DOR), time and duration of MRD negativity, and incidence and severity of adverse events (AEs). Response was assessed per International Myeloma Working Group criteria and AEs were graded by Common Terminology Criteria for Adverse Events version 5.0 (cytokine release syndrome [CRS] and immune effector cell-associated neurotoxicity syndrome [ICANS] by American Society for Transplantation and Cellular Therapy). Results: As of April 15, 2021 (median follow-up of 9.7 mo), 20 pts (65% men;median age 60 y [range 38-75]) received cilta-cel, with 1 pt treated in an outpatient setting. Pts had a median of 2 prior LOT (range 1-3);60% had 1-2 prior LOT and 40% had 3 prior LOT. All pts were exposed to a PI, IMiD, and dexamethasone;95% were exposed to alkylating agents and 65% to daratumumab. 95% of pts were refractory to last LOT;40% were triple-class refractory. ORR was 95% (95% CI 75.1-99.9);85% (95% CI 62.1-96.8) had ≥complete response (CR), and 95% (95% CI 75.1-99.9) had ≥very good partial response (Figure). Median time to first response was 1.0 mo (range 0.7-3.3) and median time to ≥CR was 2.6 mo (range 0.9-7.9). Median DOR was not reached;progression-free survival (PFS) at 6 mo was 90% (95% CI 65.6-97.4). Of 13 MRD-evaluable pts, 92.3% (95% CI 64.0-99.8) were MRD-negative at 10-5. Hematologic AEs (≥20% of pts) were neutropenia (95%;grade [gr] 3/4: 95%), thrombocytopenia (80%;gr 3/4: 35%), anemia (75%;gr 3/4: 45%), lymphopenia (65%;gr 3/4: 60%) and leukopenia (55%;gr 3/4: 55%). 95% of pts had CRS (gr 3/4: 10%);median time to onset was 7 d (range 5-9) and median duration was 4 d (range 2-11). Four pts (20%) had CAR-T neurotoxicity (all gr 1/2). Three pts (15%) had ICANS (all gr 1/2);median time to onset was 8 d (range 7-10) and median duration was 3 d (range 1-3). One pt had facial paralysis (gr 2) with time to onset of 29 d and duration of 51 d. No movement and neurocognitive treatment-emergent adverse events (TEAEs) were reported. One death due to COVID-19 was assessed as treatment-related. Safety was manageable in the pt treated in an outpatient setting. Conclusions: A single cilta-cel infusion led to early and deep responses in pts with MM who had 1-3 prior LOT and were lenalidomide-refractory. No movement and neurocognitive TEAEs occurred, suggesting successful implementation of monitoring and pt management strategies across phase 2/3 studies in the CARTITUDE program.

14.
Respir Med Res ; 81: 100904, 2022 May.
Article in English | MEDLINE | ID: covidwho-1900123

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly, becoming a major threat to global health. In addition to having required the adaptation of healthcare workers for almost 2 years, it has been much talked about, both in the media and among the scientific community. Beyond lung damage and respiratory symptoms, the involvement of the cardiovascular system largely explains COVID-19 morbimortality. In this review, we emphasize that cardiovascular involvement is common and is associated with a worse prognosis, and that earlier detection by physicians should lead to better management. First, direct cardiac involvement will be discussed, in the form of COVID-19 myocarditis, then secondary cardiac involvement, such as myocardial injury, myocardial infarction and arrhythmias, will be considered. Finally, worsening of previous cardiovascular disease as a result of COVID-19 will be examined, as well as long-term COVID-19 effects and cardiovascular complications of COVID-19 vaccines.


Subject(s)
COVID-19 , Myocarditis , COVID-19/complications , COVID-19 Vaccines , Humans , Myocarditis/complications , Myocarditis/etiology , Pandemics , SARS-CoV-2
16.
British Journal of Haematology ; 197(SUPPL 1):34-35, 2022.
Article in English | EMBASE | ID: covidwho-1861221

ABSTRACT

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell (CAR-T) therapy expressing two B-cell maturation antigen (BCMA)-targeting, singledomain antibodies. The multicohort, open-label, phase 2 CARTITUDE-2 study (NCT04133636) is evaluating ciltacel in patients (pts) with multiple myeloma (MM) in various clinical settings and assessing the suitability of outpatient administration. Updated results from CARTITUDE-2 cohort A are presented here. Cohort A pts had progressive MM after 1-3 prior lines of therapy (LOT;included proteasome inhibitor [PI] and immunomodulatory drug [IMiD]), were lenalidomide-refractory, and had no previous exposure to agents targeting BCMA. A single cilta-cel infusion at a target dose of 0.75 × 106 CAR+ viable T cells/kg was given 5-7 days after start of lymphodepletion (cyclophosphamide [300 mg/m2 ] and fludarabine [30 mg/m2 ] for 3 days). The primary endpoint was minimal residual disease (MRD) negativity at 10 -5 at any time point. Secondary endpoints were overall response rate (ORR), duration of response (DOR), time and duration of MRD negativity and adverse events (AEs). Response was assessed by International Myeloma Working Group criteria and AEs were graded by Common Terminology Criteria for Adverse Events version 5.0 (cytokine release syndrome [CRS] and immune effector cell-associated neurotoxicity syndrome [ICANS] by American Society for Transplantation and Cellular Therapy). As of April 15, 2021 (median follow-up 9.7 months), 20 pts (65% men;median age 60 years [range 38-75]) received ciltacel, with 1 pt treated in an outpatient setting. Pts had a median of two prior LOT (range 1-3);60% with 1-2 prior LOT and 40% with three prior LOT. All pts were exposed to a PI, IMiD and dexamethasone;95% were exposed to alkylating agents and 65% to daratumumab. 95% of pts were refractory to last LOT;40% were triple-class refractory. ORR was 95% (95% CI 75.1-99.9);85% (95% CI 62.1-96.8) had ≥complete response (CR), and 95% (95% CI 75.1-99.9) had ≥very good partial response. The median time to first response was 1.0 months (range 0.7-3.3) and the median time to ≥CR was 2.6 months (range 0.9-7.9). The median DOR was not reached;progression-free survival (PFS) at 6 months was 90% (95% CI 65.6-97.4). Of MRD-evaluable pts ( n = 13), 92.3% (95% CI 64.0-99.8) were MRD-negative at 10 -5 . Haematological AEs (≥20% of pts) were neutropenia (95%;grade [gr] 3/4: 95%), thrombocytopenia (80%;gr 3/4: 35%), anaemia (75%;gr 3/4: 45%), lymphopenia (65%;gr 3/4: 60%) and leukopenia (55%;gr 3/4: 55%). Ninety-five percent of pts had CRS (gr 3/4: 10%);median time to onset was 7 days (range 5-9) and median duration was 4 days (range 2-11). Four pts (20%) had CAR-T neurotoxicity (all gr 1/2). Three pts (15%) had ICANS (all gr 1/2);median time to onset was 8 days (range 7-10) and median duration was 3 days (range 1-3). One pt had facial paralysis (gr 2) with time to onset of 29 days and duration of 51 days. No movement and neurocognitive treatment-emergent adverse events (TEAEs) occurred. One death occurred due to COVID-19 (assessed as treatment-related). Safety was manageable in the pt treated in an outpatient setting. Lenalidomide-refractory pts with MM and 1-3 prior LOT showed early and deep responses with a single cilta-cel infusion. No movement and neurocognitive TEAEs were reported, suggesting utilisation of successful monitoring and pt management strategies across phase 2/3 studies in the CARTITUDE program.

17.
Hematology, Transfusion and Cell Therapy ; 43:S255, 2021.
Article in English | EMBASE | ID: covidwho-1859623

ABSTRACT

Objectives: Cilta-cel is a CAR-T cell therapy that expresses 2 BCMA-targeting single-domain antibodies, designed to confer avidity. In the multicohort, phase 2 CARTITUDE-2 study (NCT04133636), the safety and efficacy of cilta-cel in various clinical settings and suitability of outpatient administration was explored in patients with multiple myeloma. Material and methods: Patients enrolled in Cohort A had progressive MM after 1–3 prior lines of therapy (LOT), including a proteasome inhibitor (PI) and immunomodulatory drug (IMiD), were lenalidomide refractory, and were naïve to BCMA-targeting agents. A single cilta-cel infusion (target dose: 0.75 × 106 CAR+ viable T cells/kg) was given 5–7 days after start of lymphodepletion (daily cyclophosphamide [300 mg/m2] and fludarabine [30 mg/m2] for 3 days). The primary outcome was minimal residual disease (MRD) 10-5 negativity. Secondary outcomes were response rates (per IMWG criteria) and safety (per CTCAE;CRS and ICANS by ASTCT). Results: As of the February 2021 data cutoff (median follow-up: 5.8 months [2.5–9.8]), 20 patients (65% male;median age 60 years [38–75]) received cilta-cel;1 patient was treated in an outpatient setting. Patients (n = 12: <3 prior LOT;n = 8: 3 prior LOT) received a median of 2 (1–3) prior LOT. All patients were exposed to PI, IMiD, and dexamethasone, 95% to alkylating agents, and 65% to daratumumab. The majority (95%) were refractory to the last LOT;40% were triple-class refractory. Overall response rate was 95% (95% CI: 75–100), 75% (95% CI: 51–91) achieved stringent CR/CR, and 85% (95% CI: 62–97) achieved ≥VGPR. Median time to first response was 1.0 month (0.7–3.3);median time to best response was 1.9 month (0.9–5.1). Median duration of response was not reached. All patients (n = 4) with MRD-evaluable samples at 10-5 at data cutoff were MRD-negative. Hematologic AEs ≥20% were neutropenia (95%;grade 3/4: 90%), thrombocytopenia (80%;grade 3/4: 35%), anemia (65%;grade 3/4: 40%), lymphopenia (60%;grade 3/4: 55%), and leukopenia (55%;all grade 3/4). 85% of patients had CRS;10% were grade 3/4. Median time to CRS onset was 7 days (5–9), with a median duration of 3.5 days (2–11). CAR-T cell neurotoxicity occurred in 20% of patients (all grade 1/2). Three patients had ICANS (n = 1: grade 1;n = 2: grade 2);median time to onset was 8 days (7–11) and median duration was 2 days (1–2). One patient had grade 2 facial paralysis;time to onset was 29 days with a duration of 51 days. One death occurred due to Covid-19 (assessed as treatment-related by investigator). The safety profile was manageable in the patient who was treated in an outpatient setting. Discussion: Updated efficacy and safety findings will inform suitability of outpatient treatment in this and other cohorts of CARTITUDE-2 as well as the CARTITUDE-4 study. Conclusion: A single cilta-cel infusion at the recommended phase 2 dose led to early and deep responses with a manageable safety profile in patients with MM who had 1–3 prior LOT.

18.
Epidemiology ; 70(SUPPL 1):S219, 2022.
Article in English | EMBASE | ID: covidwho-1853988

ABSTRACT

Background: Mortality from COVID increases with age, but most older adults survive. Little is known about disability after COVID hospitalization. Methods: We enrolled 341 adults ≥60 years during their index COVID hospitalization between 7/2020-6/2021 from 5 hospitals. Participants underwent assessment of baseline (pre-hospital) disability, frailty, general health, social support, hearing, vision, mental health, & in-hospital symptom burden and cognitive function. Assessments were linked to health record data, including comorbidities, SOFA score, biomarkers, respiratory support, & COVID-specific treatments. Disability in 15 functional activities was assessed again at 1, 3, and 6 months. The primary outcome was mean disability count over 6 months after discharge. The analytic sample included 304 participants with ≥1 post-discharge follow-up. We evaluated 27 factors for their association with the primary outcome using backward selection with a zero-inflated negative binomial distribution & adjustment for baseline disability & months of follow-up. Results: Mean age was 71.2 yrs (SD 8.5);52% were women and 36% of nonwhite race or Hispanic ethnicity. Mean baseline disability count was 2.2 (SD 3.4). Mean disability count over the 6 months after discharge was 2.9 (SD 3.7). Greater baseline disability, older age, higher BMI, higher comorbidity count, cognitive dysfunction, greater symptom burden, and need for advanced respiratory support were associated with greater post-hospitalization disability (Table). Conclusions: Baseline vulnerability factors as well as in-hospital symptom burden, cognitive dysfunction, and advanced respiratory support were associated with increased disability after a COVID hospitalization. There was no association with COVIDspecific treatments or biomarkers. These factors may identify older adults with the most potential to benefit from efforts to improve functional recovery.

19.
PubMed; 2021.
Preprint in English | PubMed | ID: ppcovidwho-334697

ABSTRACT

BACKGROUND: Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time. OBJECTIVE: To determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals. METHODS: Antibody titers were measured between January 31, 2021, and July 31, 2021 in two mutually exclusive groups: i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and ii) SARS-CoV-2 convalescents who had not received the vaccine. RESULTS: A total of 2,653 individuals fully vaccinated by two doses of vaccine during the study period and 4,361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination, than in convalescent individuals (median 355.3 AU/mL IQR [141.2-998.7];p<0.001). In vaccinated subjects, antibody titers decreased by up to 40% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection. CONCLUSIONS: This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group. FUNDING: This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. IMPACT STATEMENT: Large scale study display the kinetics of SARS-CoV-2 IgG antibodies present in individuals vaccinated with two doses of mRNA vaccine vs. unvaccinated patients who had recovered from the disease: initial levels of antibody are much higher in vaccinated patients, but decrease faster.

20.
Frontiers in Sustainable Cities ; 4, 2022.
Article in English | Scopus | ID: covidwho-1789417

ABSTRACT

Public participation processes influencing National Forest management in the United States have shifted significantly because of the global COVID-19 pandemic. Although the United States Forest Service has used virtual participation tools in the past to support participation, the pandemic was the first time staff had to solely rely on such methods. Using the Trinity of Voice theory concepts of access, standing, and influence, we discuss how each has been and can be impacted by virtual vs. in-person public participation in federal land governance. Lessons are drawn from two peer-to-peer learning sessions among Forest Service staff in Fall 2020 and a case from the National Forests in North Carolina. Virtual participation can broaden access to processes that would primarily have taken place in-person as people were not limited by travel time or distance. Virtual methods may allow for greater use of adaptive technologies and therefore may increase participation access. Web meeting alternatives (e.g., telephone calls) can be used to increase participation access for those without reliable or affordable internet. However, planners trained in facilitating in-person meetings may not have the technical competencies necessary to ensure participants are able to effectively participate during virtual meetings, and misunderstandings that might be easily addressed in face-to-face settings can be more difficult to solve and ground rules for participation ignored more easily during virtual participation. We expect these lessons will support the work of other practitioners interested in supporting access, standing, and influence when designing virtual participation processes. Copyright © 2022 Floress and Cohen.

SELECTION OF CITATIONS
SEARCH DETAIL